Literature DB >> 2334892

Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment.

F Takatsuki1, A Okano, C Suzuki, Y Miyasaka, T Hirano, T Kishimoto, D Ejima, Y Akiyama.   

Abstract

Effects of interleukin 6 (IL-6) on the functional capacity of the immune and hematopoietic systems in 5-fluorouracil (5-FU)-treated mice were determined. IL-6 (5 x 10(4) units/mouse/day) was administered s.c. for 7 days by implantation of an osmotic pump, since it was demonstrated that a much higher increase in the primary response to sheep RBC was observed by administration of slowly released rather than daily s.c. injection of IL-6. IL-6 perfusion significantly augmented anti-sheep RBC antibody responses depressed by 5-FU (150 mg/kg) treatment. IL-6 also was shown to stimulate hematological recovery in mice treated with 5-FU. Namely, IL-6 perfusion accelerated the recovery of the number of hematopoietic stem cells, granulocyte-macrophage progenitors, and mature neutrophils in the spleen, although IL-6 did not stimulate the recovery of the neutrophil count in blood. Recovery of the platelet count in blood was stimulated by IL-6. Furthermore, it was found that the endogenous IL-6 level in serum increased after 5-FU treatment, which suggests that IL-6 may play some role in the recovery of the immune and hematopoietic systems. Finally, we examined the effect of IL-6 on the survival of mice treated with a higher dosage of 5-FU (300 mg/kg). IL-6 perfusion produced a distinct increase in survival rate at Day 30 (74% versus 28%). It is of note that the number of bacteria (identified as Escherichia coli) cultured from the spleen and the liver decreased in IL-6-perfused mice. This IL-6-induced effect was accompanied by enhancement of an oxidative burst response. Moreover, the anti-E. coli antibody titer in serum was higher in IL-6-perfused mice than in control mice. These results suggest the possible use of IL-6 for stimulating the reconstitution of the immune and hematopoietic systems after chemotherapy treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2334892

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Pentoxifylline enhances the radioprotective properties of γ-tocotrienol: differential effects on the hematopoietic, gastrointestinal and vascular systems.

Authors:  Maaike Berbée; Qiang Fu; Sarita Garg; Shilpa Kulkarni; K Sree Kumar; Martin Hauer-Jensen
Journal:  Radiat Res       Date:  2010-12-28       Impact factor: 2.841

2.  The effect of interleukin-6 on bacterial translocation in acute canine pancreatitis.

Authors:  Q Liu; G Djuricin; C Nathan; P Gattuso; R A Weinstein; R A Prinz
Journal:  Int J Pancreatol       Date:  2000-04

3.  Gamma interferon (IFN-gamma) and IFN-gamma-inducing cytokines interleukin-12 (IL-12) and IL-18 do not augment infection-stimulated bone resorption in vivo.

Authors:  Hajime Sasaki; Khaled Balto; Nobuyuki Kawashima; Jean Eastcott; Katsuaki Hoshino; Shizuo Akira; Philip Stashenko
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

4.  Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow.

Authors:  H Kitamura; H Kawata; F Takahashi; Y Higuchi; T Furuichi; H Ohkawa
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

5.  Interleukin-6 and granulocyte colony-stimulating factor synergistically increase peripheral blood progenitor cells in myelosuppressive mice.

Authors:  H Suzuki; A Okano; C Ejima; A Konishi; Y Akiyama; K Ozawa; S Asano
Journal:  Jpn J Cancer Res       Date:  1996-09

6.  Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus.

Authors:  R G Hawley; A Z Fong; B F Burns; T S Hawley
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

7.  Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.

Authors:  Bojidar M Kojouharov; Craig M Brackett; Jean M Veith; Christopher P Johnson; Ilya I Gitlin; Ilia A Toshkov; Anatoli S Gleiberman; Andrei V Gudkov; Lyudmila G Burdelya
Journal:  Oncotarget       Date:  2014-02-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.